Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacological Prevention vs Pancreatic Stents Plus Pharmacological Prevention for Post-ERCP Pancreatitis
NCT02368795Unknown
- Sponsor
- Tehran University of Medical Sciences
- Start
- Feb 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of indomethacin, isosorbide dinitrate and lactated ringer's solution in pancreatitis (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Incidence of Post-ERCP pancreatitis at 24 hours. Status: unknown.
02
Drugs
indomethacinisosorbide dinitratelactated ringer's solution
03
Conditions
pancreatitis
Beyond the preview
Go deeper on NCT02368795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02368795.